Apr 16, 2018
NCCN Roundtable and Keynotes Address: How to Define and Find Value in Cancer Care
Apr 05, 2018
Parker Institute for Cancer Immunotherapy Scientists to Present Immuno-oncology Research on Personalized Cancer Vaccines, New Checkpoint Inhibitor Combinations, the Microbiome and Cell Therapy at AACR 2018
Apr 03, 2018
Bridge Medicines Appoints Louis M. Renzetti, Ph.D., As Chief Scientific Officer
Mar 28, 2018
Malnati Brain Tumor Institute Celebrates 10-Year Anniversary at Annual Minds Matter Benefit Dinner
Mar 14, 2018
Bridge Medicines Accepts Novel Small Molecule Targeting Basal Cell Carcinoma As First Drug Candidate for Development
Mar 05, 2018
The Memorial Sloan Kettering - Hackensack Meridian Health Partnership to Host Cancer Science Today: A Community Education Talk Series
Mar 02, 2018
Cycle for Survival Awarded Program Of The Year By The Peer-to-Peer Professional Forum
Feb 28, 2018
Personal Genome Diagnostics Expands Its Tumor Mutational Burden (TMB) Patent Portfolio for Cancer Immunotherapy
Jan 11, 2018
TAG Heuer, The Avant-Garde Swiss Watchmaker, Launches First Celebrity Fundraising Challenge Benefiting Cycle for Survival
Jan 03, 2018
Baptist Health South Florida Selects Cota, Inc. to Advance Personalized Cancer Treatment and Research
Dec 07, 2017
Wattstopper® Lighting Controls Contribute to Improving the Occupant Experience at Memorial Sloan Kettering Monmouth
Nov 09, 2017
Cota Announces Data and Technology Collaboration with Memorial Sloan Kettering Cancer Center to Advance Personalized Cancer Treatment and Research
Sep 27, 2017
Cycle For Survival Launches 2018 Battle To Beat Rare Cancers In Times Square
Sep 07, 2017
NCCN Announces First Patient Dosed in NCCN-Peregrine Pharmaceuticals Collaborative Study of Bavituximab
Sep 01, 2017
Cycle for Survival Invests $34 Million in Rare Cancer Research in 2017
Aug 03, 2017
Senate passes the RACE for Children Act!
Jun 22, 2017
The Parker Institute for Cancer Immunotherapy Trains the Next Generation of Scientific Leaders in Cancer Immunotherapy
Jun 01, 2017
Philips and Memorial Sloan Kettering Cancer Center announce research agreement to jointly develop advanced genome analytics for precision oncology
Jun 01, 2017
At ASCO 2017 Clinicians Present New Evidence about Watson Cognitive Technology and Cancer Care
May 31, 2017
MabVax Therapeutics Signs Research Agreement with Memorial Sloan Kettering Cancer Center to Develop Novel CAR T-Cell Based Anti-Cancer Immunotherapies for Treatment of Pancreatic and Small Cell Lung Cancers